Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

Ria Lassaunière; Charlotta Polacek; Anders Frische; Lasse Boding; Susanne Gjørup Sækmose; Morten Rasmussen; Anders Fomsgaard

doi:10.1001/jamanetworkopen.2022.12073

Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine

JAMA Netw Open. 2022 May 2;5(5):e2212073. doi: 10.1001/jamanetworkopen.2022.12073.

Authors

Ria Lassaunière¹, Charlotta Polacek¹, Anders Frische¹, Lasse Boding², Susanne Gjørup Sækmose³, Morten Rasmussen¹, Anders Fomsgaard¹

Affiliations

¹ Department of Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
² Danish National Biobank, Statens Serum Institut, Copenhagen, Denmark.
³ Department of Clinical Immunology, Zealand University Hospital, Naestved, Denmark.

Abstract

This cohort study examines neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) after the second and third doses of the BNT162b2 mRNA vaccine among Danish adults.

MeSH terms

Antibodies, Neutralizing
BNT162 Vaccine
COVID-19* / prevention & control
Humans
SARS-CoV-2* / genetics
Vaccines, Synthetic
mRNA Vaccines

Substances

Antibodies, Neutralizing
Vaccines, Synthetic
mRNA Vaccines
BNT162 Vaccine

Supplementary concepts

SARS-CoV-2 variants